Journal of Molecular Neuroscience

, Volume 64, Issue 2, pp 262–272 | Cite as

YAP Promotes Migration and Invasion of Human Glioma Cells

  • Yu Zhang
  • Peng Xie
  • Xu Wang
  • Peng Pan
  • Yan Wang
  • Hao Zhang
  • Yu Dong
  • Yi Shi
  • Yang Jiang
  • Rutong YuEmail author
  • Xiuping ZhouEmail author


Previously, we have reported that Yes-associated protein (YAP) is upregulated in human glioma tissues and its level is positively correlated with patient prognosis. However, the role and mechanism of YAP in the highly invasive nature of human gliomas were largely unknown. In this study, examined by wound healing assay, transwell assay, or live-imaging, we found that YAP downregulation inhibited glioma cell migration and invasion, while YAP over-expression promoted them. Interestingly, the above effect of YAP on immortalized glioma cells was recapitulated in cultured primary glioma cells. In addition, the protein level of N-cadherin and Twist, two important proteins involved in tumor invasion, increased after YAP over-expression. Meanwhile, YAP over-expression significantly increased the F-actin level and changed the distribution of F-actin, leading to cytoskeletal reorganization, which plays an important role in cell motility. Furthermore, the promotion effect of YAP over-expression on glioma cell migration and invasion was partially abolished by Twist downregulation. Taken together, our findings show that YAP contributes to glioma cell migration and invasion by regulating N-cadherin and Twist, as well as cytoskeletal reorganization.


Glioma YAP Migration F-actin N-cadherin Twist 



We thank Professor Chunmei Zhu in the School of International Education of Xuzhou Medical University for the English writing assistance.

Funding Information

This study was supported by National Natural Science Foundation of China (No. 81372699; No. 81672489; No.81472345) and the Six Major Talent Summit of Jiangsu Province (No. WSW-039).

Compliance with Ethical Standards

Written informed consent was obtained from the patients and the study was approved by the ethics committee of the hospital.

Supplementary material

12031_2017_1018_FIG6_ESM.gif (100 kb)
Supplemental Figure 1

(GIF 99 kb)

12031_2017_1018_MOESM1_ESM.tif (3.5 mb)
High resolution (TIFF 3563 kb)
12031_2017_1018_FIG7_ESM.gif (193 kb)
Supplemental Figure 2

(GIF 193 kb)

12031_2017_1018_MOESM2_ESM.tif (7.7 mb)
High resolution (TIFF 7909 kb)
12031_2017_1018_FIG8_ESM.gif (80 kb)
Supplemental Figure 3

(GIF 79 kb)

12031_2017_1018_MOESM3_ESM.tif (2.6 mb)
High resolution (TIFF 2644 kb)
12031_2017_1018_FIG9_ESM.gif (78 kb)
Supplemental Figure 4

(GIF 78 kb)

12031_2017_1018_MOESM4_ESM.tif (2.7 mb)
High resolution (TIFF 2763 kb)

(WMV 5622 kb)


(WMV 28129 kb)


(WMV 7955 kb)


(WMV 28804 kb)


  1. Artinian N, Cloninger C, Holmes B, Benavides-Serrato A, Bashir T, Gera J (2015) Phosphorylation of the Hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP signaling, resulting in enhanced glioblastoma growth and invasiveness. J Biol Chem 290(32):19387–19401. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Cavallaro U, Christofori G (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4(2):118–132. CrossRefPubMedGoogle Scholar
  3. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130(6):1120–1133. CrossRefPubMedPubMedCentralGoogle Scholar
  4. Edgar BA (2006) From cell structure to transcription: Hippo forges a new path. Cell 124(2):267–273. CrossRefPubMedGoogle Scholar
  5. Espanel X, Sudol M (2001) Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. J Biol Chem 276:14514–14523. CrossRefPubMedGoogle Scholar
  6. H C YX (2013) The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells. Cell Commun Signal 11(1):31. CrossRefGoogle Scholar
  7. Hergovich A (2012) YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer. Breast Cancer Res : BCR 14(6):326. CrossRefPubMedPubMedCentralGoogle Scholar
  8. Howell M, Borchers C, Milgram SL (2004) Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription. J Biol Chem 279(25):26300–26306. CrossRefPubMedGoogle Scholar
  9. Hsu YL, Hung JY, Chou SH, Huang MS, Tsai MJ, Lin YS, Chiang SY, Ho YW, Wu CY, Kuo PL (2015) Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression. Oncogene 34(31):4056–4068. CrossRefPubMedGoogle Scholar
  10. Huang J, Wu S, Barrera J, Matthews K, Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 122(3):421–434. CrossRefPubMedGoogle Scholar
  11. Komuro A, Nagai M, Navin NE, Sudol M (2003) WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278(35):33334–33341. CrossRefPubMedGoogle Scholar
  12. Lacroix M et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme. J Neurosurg 95(2):190–198. CrossRefPubMedGoogle Scholar
  13. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A. Gray N, Zarate CA Jr, Charney DS (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53(8):707–742. CrossRefPubMedGoogle Scholar
  14. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, Janssen I, Giangaspero F, Forni M, Finocchiaro G, Genitori L, Giordano F, Riccardi R, Schoenmakers EFPM, Massimino M, Sozzi G (2006) Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol : Off J Am Soc Clin Oncol 24(33):5223–5233. CrossRefGoogle Scholar
  15. Nurnberg A, Kitzing T, Grosse R (2011) Nucleating actin for invasion. Nat Rev Cancer 11(3):177–187. CrossRefPubMedGoogle Scholar
  16. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103(33):12405–12410. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre J-Y (2012) Primary brain tumours in adults. Lancet 379(9830):1984–1996. CrossRefPubMedGoogle Scholar
  18. RN J et al (2012) The Hippo pathway member Yap plays a key role in influencing fate decisions in muscle satellite cells. J Cell Sci 125(24):6009–6019. CrossRefGoogle Scholar
  19. SK Z et al (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004:790–799.
  20. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, Montgomery EA, Anders RA (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39(11):1582–1589. CrossRefPubMedPubMedCentralGoogle Scholar
  21. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, del Sal G, Levrero M, Blandino G (2005) The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol Cell 18(4):447–459. CrossRefPubMedGoogle Scholar
  22. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276(18):15164–15173. CrossRefPubMedGoogle Scholar
  23. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. CrossRefPubMedGoogle Scholar
  24. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60(3):166–193. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H (2011) Hippo pathway regulation by cell morphology and stress fibers. Development 138(18):3907–3914. CrossRefPubMedGoogle Scholar
  26. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101(5):1279–1285. CrossRefPubMedGoogle Scholar
  27. Wang Y et al (2017) Beta-catenin-mediated YAP signaling promotes human glioma growth. J Exp Clin Cancer Res : CR 36:136. CrossRefPubMedPubMedCentralGoogle Scholar
  28. Yagi R, Chen L-F, Shigesada K, Murakami Y, Ito Y (1999) A WW domain-containing Yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18(9):2551–2562. CrossRefPubMedPubMedCentralGoogle Scholar
  29. Yang S et al (2015) Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget 6:36019–36031. PubMedPubMedCentralGoogle Scholar
  30. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125(7):1253–1267. CrossRefPubMedPubMedCentralGoogle Scholar
  31. Zhang H, von Gise A, Liu Q, Hu T, Tian X, He L, Pu W, Huang X, He L, Cai CL, Camargo FD, Pu WT, Zhou B (2014) Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion. J Biol Chem 289(27):18681–18692. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, Fu K, Datta K, Palermo N, Chen Y, Dong J (2015a) The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol 35(8):1350–1362. CrossRefPubMedPubMedCentralGoogle Scholar
  33. Zhang X, Ding Z, Mo J, Sang B, Shi Q, Hu J, Xie S, Zhan W, Lu D, Yang M, Bian W, Zhou X, Yu R (2015b) GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. Mol Carcinog 54(11):1252–1263. CrossRefPubMedGoogle Scholar
  34. Zhang H, Geng D, Gao J, Qi Y, Shi Y, Wang Y, Jiang Y, Zhang Y, Fu J, Dong Y, Gao S, Yu R, Zhou X et al (2016) Expression and significance of Hippo/YAP signaling in glioma progression tumour biology. J Int Soc Oncodev Biol Med 37(12):15665–15676.
  35. Zhao B, Li L, Lei Q, Guan KL (2010) The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24(9):862–874. CrossRefPubMedPubMedCentralGoogle Scholar
  36. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL (2012) Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26(1):54–68. CrossRefPubMedPubMedCentralGoogle Scholar
  37. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21(21):2747–2761. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Graduate SchoolXuzhou Medical UniversityXuzhouChina
  2. 2.Department of NeurosurgeryHuaian Second People’s HospitalHuaianChina
  3. 3.Brain HospitalAffiliated Hospital of Xuzhou Medical UniversityXuzhouPeople’s Republic of China
  4. 4.Institute of Nervous System DiseasesXuzhou Medical UniversityXuzhouPeople’s Republic of China

Personalised recommendations